Tag: OSE230
OSE Immunotherapeutics: partnership with AbbVie for OSE-230
By Arnaud Bivès Published on 02/28/2024 at 7:57 a.m. (Boursier.com) — OSE Immunotherapeutics and AbbVie announce a…
OSE Immunotherapeutics: publication on OSE-230 in ‘Frontiers in Immunology’
By Alexandra Saintpierre Published on 07/19/2023 at 6:33 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the publication,…
OSE Immunotherapeutics: new publication on the OSE-230 antibody – 07/19/2023 at 18:21
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics: new publication on the OSE-230 antibody
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics presents the latest data on the BiCKI®IL-7, CLEC-1 and OSE-230 preclinical programs in Immuno-Oncology and Immuno-Inflammation At international conferences – 06/15/2023 at 07:30
Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations…